Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
Status:
Not yet recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test the efficacy and safety of the Chinese patent
medicine Changyanning Tablet in the patients with Diarrhea-Predominant Irritable Bowel
Syndrome (IBS-D). The main questions it aims to answer are:
1. Can Changyanning Tablet improve diarrhea and abdominal pain in IBS-D patients?
2. Is Changchangning Tablet safe for the treatment of IBS-D?